New Horizon Medical Solutions Partners with Soring to Expand Access to Ultrasonic Wound Debridement Technology

New Horizon Medical Solutions (NHMS) has announced a strategic collaboration with Soring, the U.S. affiliate of Söring (Germany), for the sale of their Ultrasonic Wound Debridement (UAW) device. This partnership is designed to enhance wound treatment across multiple healthcare environments by integrating advanced technology into clinical practice. The Söring Ultrasonic-Assisted Wound debridement system includes an ultrasonic generator and instrument, intended for debridement and cleansing of chronic and acute wounds. The system effectively removes fibrin tissues such as necroses, fibrin, scab, and pus, while also breaking up biofilms, which is crucial for improving wound status and promoting healing in conditions like diabetic foot syndrome, decubitus ulcers, burns, and post-surgical or post-traumatic wounds.

Jeffrey Alan Niezgoda, MD, FACHM, MAPWCA, CHWS, Chief Medical Officer of Kent Imaging and board member of NHMS, emphasized the clinical significance of this technology. He stated that using the SONOCA 185 and UAW instruments for ultrasonic wound debridement, when guided by SnapshotGLO and monitored by SnapshotNIR, can significantly improve wound management and lead to better patient outcomes. These devices work synergistically to optimize wound bed preparation prior to the application of Cellular and/or Acellular Matrices and Placental (CAMPs) products, which are part of NHMS's portfolio. This integration represents a comprehensive approach to advanced wound care, addressing both the debridement and subsequent healing phases.

Will Hall, CEO of New Horizon Medical Solutions, highlighted the strategic importance of the collaboration. He noted that it reflects NHMS's belief that the future of wound care lies in combining advanced technology with evidence-based clinical solutions. By incorporating Söring's ultrasonic system into their offerings, NHMS aims to expand access to innovative tools that address critical gaps in treatment while improving efficiency and outcomes across various care settings. This move aligns with NHMS's commitment to delivering biologically derived human placental allograft products, such as amniotic membranes, placental tissues, and skin grafts, which are used for chronic wounds, surgical reconstruction, burns, and orthopedic procedures.

Söring, founded in 1985 and headquartered in Germany, specializes in ultrasonic tissue resection and ablation, developing medical technologies used globally by healthcare professionals. The company focuses on pushing the boundaries of modern surgery and enhancing patient outcomes through intuitive user experience and direct service. This collaboration leverages Söring's expertise in ultrasonic technology with NHMS's focus on advanced wound care solutions, potentially making surgical procedures more efficient, safer, and easier to perform. The partnership is structured as an independent contracting arrangement, with both parties maintaining their separate operational identities while working together to distribute the UAW device in the U.S. market.

The implications of this announcement are significant for the healthcare industry, particularly in wound care management. By combining NHMS's biologically derived products with Söring's ultrasonic debridement technology, the collaboration aims to provide a more integrated and effective treatment pathway for patients with complex wounds. This could lead to reduced healing times, lower infection rates, and improved overall patient outcomes, addressing a growing need in an aging population and among patients with chronic conditions like diabetes. The focus on evidence-based design and precision manufacturing, as emphasized by NHMS, ensures that these advancements are grounded in clinical research and safety standards, potentially setting new benchmarks in wound care protocols and accessibility to cutting-edge medical devices.